Sub Rosa

Sub Rosa Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in the development of small molecule therapeutics that target RNA. The company's mission is to unlock the therapeutic potential of the non-coding genome and complex RNA structures that drive disease. By utilizing a proprietary platform that integrates RNA biology, structural biology, and medicinal chemistry, Sub Rosa identifies druggable pockets within RNA molecules. This approach allows for the modulation of gene expression and protein production in ways that traditional protein-targeting drugs cannot achieve. The company was co-founded by renowned scientist and entrepreneur Gregory Verdine and is led by CEO Nenad Grmusa. Sub Rosa is currently advancing a pipeline of preclinical programs primarily focused on oncology and other high-need therapeutic areas. Backed by leading venture capital firms like F-Prime Capital, the company represents a significant effort in the emerging field of RNA-targeted small molecule medicine.